Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 
CHEMOCENTRYX, INC.
(Name of Issuer)

Common Stock, $0.001 Par Value
(Title of Class of Securities)

 16383L106(CUSIP Number)

Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 17, 2013
(Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  o

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
 
 
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 2 of 7  
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
GlaxoSmithKline plc
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                                                                            (a) o
                                                                                                                            (b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)    o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
WITH
7
SOLE VOTING POWER
 7,343,492
8
SHARED VOTING POWER
-0-
9
SOLE DISPOSITIVE POWER
7,343,492
10
SHARED DISPOSITIVE POWER
-0-
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,343,492 shares of Common Stock (1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES        o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.2% of the shares of Common Stock (2)
14
TYPE OF REPORTING PERSON
CO
 
Footnotes:
 
(1)       Shares held of record by Glaxo Group Limited, a wholly owned subsidiary of the Reporting Person, issued as of  February 13, 2012.
 
(2)       Based on 42,594,905 shares of Common Stock as of April 17, 2013.
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 3 of 7  
 

 
This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on February 23, 2012 (the “Original Schedule 13D”) with respect to the shares of common stock, par value $0.001 per share (the “Common Stock”), of ChemoCentryx, Inc., a Delaware corporation (the “Issuer”).  Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.
 
Item 2.         Identity and Background.
 
The response set forth in Item 2 of the Original Schedule 13D is hereby amended by deleting Schedule 1 in its entirety, and replacing it with Schedule 1 attached hereto.
 
Item 5.         Interest in Securities of the Issuer.
 
The response set forth in the first paragraph of Item 5 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
 
(a) GlaxoSmithKline plc beneficially owns 7,343,492 shares of Common Stock, issued as of February 13, 2012, which represents 17.2% of the 42,594,905 shares of Common Stock outstanding as of April 17, 2013.  The Issuer issued an additional 5,750,000 shares of Common Stock on April 17, 2013.
 
 
 
 
 
 
 
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 4 of 7  
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
 

 
 
GLAXOSMITHKLINE PLC
   
   /s/ Victoria A. Whyte              
 
By: Victoria A. Whyte
Title: Company Secretary
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 5 of 7  
 
 SCHEDULE I

Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
             
Board of Directors
            
             
Sir Andrew Witty
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Executive Officer
  
British
             
Simon Dingemans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Financial Officer
  
British
             
Dr. Moncef Slaoui
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director
Chairman Global Research & Development and Vaccines
  
Moroccan, Belgian & US
             
Sir Christopher Gent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chairman and Company Director
  
British
             
Professor Sir Roy Anderson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Dr. Stephanie Burns
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Stacey Cartwright
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Sir Crispin Davis*
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Judy Lewent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
 
             
Sir Deryck Maughan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
 
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 6 of 7  
 
Dr. Daniel Podolsky
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Tom de Swaan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
Dutch
             
Sir Robert Wilson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Lynn Elsenhans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Jing Ulrich
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Hans Wijers
 
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
 
  
Company Director
  
Dutch
*Sir Crispin Davis will not stand for re-election at the Annual General Meeting on May 1, 2013.
 
 
Corporate Executive Team
      
       
Sir Andrew Witty
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Chief Executive Officer
British
       
Simon Dingemans
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Executive Director and Chief Financial Officer
British
       
Dr. Moncef Slaoui
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Executive Director
Chairman Global Research & Development and Vaccines
Moroccan, Belgian & US
 
 
 
 
 
CUSIP No.             16383L106
 
SCHEDULE 13D/A
Page 7 of 7  
 
Simon Bicknell
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Senior Vice President, Governance, Ethics and Assurance
British
       
Deirdre Connelly
1600 Vine Street,
Philadelphia, PA
19102
President, North America
Pharmaceuticals
US
       
Abbas Hussain
150 Beach Road
22-00 Gateway West
189720
Singapore
President, Europe & Emerging Markets & Asia Pacific
 
British
       
William Louv
Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709
Senior Vice President, Core Business Services & Chief Information Officer
US
       
David Redfern
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Chief Strategy Officer
British
       
Christophe Weber
Avenue Fleming, 20
B-1300 Wavre
Belgium
President, Vaccines
French
       
Claire Thomas
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Senior Vice President,
Human Resources
British
       
Philip Thomson
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
Senior Vice President, Global Communications
British
       
Daniel Troy
One Franklin Plaza
Philadelphia, PA
19102
Senior Vice President & General Counsel
US
       
Dr. Patrick Vallance
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
President, Pharmaceuticals R&D
British
       
Emma Walmsley
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
President, Consumer Healthcare Worldwide
British
       
Roger Connor
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
President, Global Manufacturing & Supply
British